COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 أبريل 2024 09:02:18 بحسب Nasdaq GlobeNewswire

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

08 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

13 مارس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

05 مارس 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Coherus Completes Divestiture of Ophthalmology Franchise

04 مارس 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

23 فبراير 2024 16:33:13 بحسب Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

21 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

05 فبراير 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

22 يناير 2024 00:15:00 بحسب Nasdaq GlobeNewswire

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

18 يناير 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of LOQTORZI™

02 يناير 2024 07:29:00 بحسب Nasdaq GlobeNewswire

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

26 ديسمبر 2023 15:01:00 بحسب Nasdaq GlobeNewswire

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

11 ديسمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Coherus BioSciences Announces CFO Transition Plans

07 ديسمبر 2023 16:55:48 بحسب Nasdaq GlobeNewswire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

06 ديسمبر 2023 03:00:00 بحسب Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

28 نوفمبر 2023 10:16:23 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

10 نوفمبر 2023 08:49:53 بحسب NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

09 نوفمبر 2023 08:46:01 بحسب NetDania Notify

NetDania - New 12 months Low: COHERUS BIOSCIENCES INC. - COMMON STOCK

08 نوفمبر 2023 09:08:07 بحسب NetDania Notify